New daily pill aims to boost growth in kids with dwarfism
NCT ID NCT07297875
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called ABSK061 in children aged 3 to 12 with achondroplasia, a common form of dwarfism. The drug is taken once daily and aims to improve growth rate. The trial will first find a safe dose, then check how well it works over a year. About 110 children will take part across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ABSK061 (a drug taken orally once daily)
What this could lead to
If successful, this could lead to a daily treatment that helps children with achondroplasia grow more than they would without treatment.
What could go wrong
This is an early-phase trial with only 110 participants, so results may not apply to all. The drug may cause side effects or fail to improve growth significantly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACHONDROPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Children's Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Contact Email: •••••@•••••
Contact
-
Chengdu Women's and Children's Central Hospital
Chengde, Sichuan, China
-
Children's Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
-
Henan Children's Hospital, Zhengzhou Children's Hospital
Zhengzhou, Henan, China
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Contact
Contact Email: •••••@•••••
Contact
-
West China Second University Hospital, Sichuan University
Chengdu, Sichuan, China
Contact Email: •••••@•••••
Contact
-
Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Contact